Drug
Zemprocitinib clinical trials
Also written LNK01001.
Keep track of what changes. Save the zemprocitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Lynk Pharmaceuticals Co., Ltd (6)
Related medicines
As reviewed, each with the page that says it.
- One of Janus Kinase Inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses zemprocitinib is read from its arms, and is right about nine times in ten.
Testing it · 6
- A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing SpondylitisRecruitingPhase 3Lynk Pharmaceuticals Co., LtdNCT07237568Written as LNK01001
- A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.CompletedPhase 3Lynk Pharmaceuticals Co., LtdNCT06277245Written as LNK01001
- A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)Active, not recruitingPhase 3Lynk Pharmaceuticals Co., LtdNCT06276998Written as LNK01001
- A Study of LNK01001 Capsule in Patients With Ankylosing SpondylitisCompletedPhase 2Lynk Pharmaceuticals Co., LtdNCT06085534Written as LNK01001
- A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic DermatitisCompletedPhase 2Lynk Pharmaceuticals Co., LtdNCT06085521Written as LNK01001 Dose A
- A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid ArthritisCompletedPhase 2Lynk Pharmaceuticals Co., LtdNCT06099535Written as LNK01001 Dose A
Codes
What other systems call zemprocitinib · ClinicalTrials.gg INT017178
- UNII (FDA) LG6MM3RP86ZEMPROCITINIBConfirmed FDA, Wikidata
- Wikidata Q140562005zemprocitinibConfirmed FDA, Wikidata
- NCI Thesaurus C207018ZemprocitinibOne source FDA
- DrugBank DB21719One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LG6MM3RP86 | ZEMPROCITINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140562005 | zemprocitinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C207018 | Zemprocitinib | One source FDA |
| DrugBank | DB21719 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.